Exactech, JointMedica announce breakthrough device designation for hip resurfacing system
Exactech, a minority shareholder of JointMedica Limited, has announced FDA breakthrough device designation for JointMedica’s Polymotion hip resurfacing system, according to an Exactech press release.
The Polymotion hip resurfacing system, which is designed to address hip osteoarthritis in young, active patients and eliminates metal-on-metal articulating surfaces, is a collaboration between Exactech and JointMedica. According to the release, Exactech holds exclusive global distribution rights to the product.
“We are thrilled that Polymotion and JointMedica have been recognized as one of only 71 orthopedic devices that have received breakthrough designation since the inception of this program,” Sharat Kusuma, MD, chief strategy officer of Exactech, said in the release. “We aspire to accelerate Polymotion hip resurfacing development and help more patients get back to all the activities they love,” Kusuma added.
“Through this deep collaboration, Exactech and JointMedica are well positioned to bring the Polymotion hip resurfacing system to the global market,” Jeff Binder, CEO and chair of the board of Exactech, said in the release. “Partnering with surgeons at the early stages of development has always served a fundamental role in our success,” he said.
Read more about